Real clinical outcomes of nivolumab plus ipilimumab for renal cell carcinoma in patients over 75 years old.

Mizuki Kobayashi,Kazuyuki Numakura,Shingo Hatakeyama,Toshiya Ishida,Atsushi Koizumi, Kazuki Tadachi,Ryoma Igarashi,Koichiro Takayama,Yumina Muto,Yuya Sekine,Ryuta Sobu,Hajime Sasagawa,Hideo Akashi,Soki Kashima,Ryohei Yamamoto,Taketoshi Nara,Mitsuru Saito,Shintaro Narita,Chikara Ohyama,Tomonori Habuchi

International journal of clinical oncology（2023）

引用 0|浏览15

暂无评分

摘要

The effectiveness of nivolumab plus ipilimumab was comparable between patients with metastatic RCC aged < 75 and those ≥ 75 years with respect to their ORRs, PFS, OS, and adverse event rates.

查看译文

关键词

renal cell carcinoma,nivolumab,ipilimumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要